ADAM15 and neoplasm: Two phase I clinical trials were initiated using a plasmid AMEP that encodes an Antiangiogenic MEtargidin Peptide derived from the disintegrin domain of human metargidin (also known as ADAM-15) which binds to α5β1 and αvβ3 integrins upregulated on endothelial cells during tumor angiogenesis.